BioLamina

BioLamina

Forskning inom bioteknik

Cell-specific culture matrices for improved cell functionality

Om oss

BioLamina is a Swedish biotechnology company with a global presence, offering cell culture matrices for primary cells. We offer an expansive portfolio of recombinant laminin proteins for a variety of applications, including the reliable expansion of pluripotent cell and differentiation and maintenance of specialized cell types. Our chemically defined and xeno-free laminin cell culture matrices allow you to imitate the natural cell-matrix interaction in vitro. Laminins are key components of the extracellular matrix. Through their interactions with specific receptors, laminins trigger the authentic cellular responses, pivotal for cell anchorage, survival, proliferation, migration, organization, and specialization, leading to improved cell functionality. BioLamina’s laminins are the only original full length, human, recombinant laminins on the market. Our high technology products contribute to our customer’s efficiency and scientific breakthroughs and enable them to start a new era in medical research. We are known and recognized for our premium products, competence, dedication, and service and position ourselves as being in the forefront of cell culturing. Our vision is to make BioLamina a leading brand within the field of cell culture and to help make cell therapy a reality. BioLamina is built on a scientific foundation with a legacy in matrix biology and solid experience in cell culture-based research. The company was started in 2009 and was co-founded by Dr. Karl Tryggvason and his son Dr. Kristian Tryggvason. Today the company has about 35 employees spanning from production, R&D, logistics, sales, and marketing. Our quality system complies with ISO 9001:2015 and both management and employees follow well-defined standard processes and agreements.

Webbplats
http://www.biolamina.com
Bransch
Forskning inom bioteknik
Företagsstorlek
51–200 anställda
Huvudkontor
Sundbyberg
Typ
Privatägt företag
Grundat
2009
Specialistområden
Cell culture, Stem cell culture and differentiation och Laminin

Adresser

Anställda på BioLamina

Uppdateringar

  • Visa organisationssidan för BioLamina, grafik

    9 760 följare

    Some cherry-picking done yesterday from Dr. Karl Tryggvason's, our scientific founder, cherry tree (with permission, we promise! 😉) All these delicious fruits are now ready for some molecular cooking. We will follow recipes / protocols to get the best results. Cherry-picking in science? No, thank you! With consistently performing cell culture, you don’t need to exclude replicates and cherry-pick data. See this example of how the chemically defined, biologically relevant Biolaminin substrate offers reproducibility in cardiomyocyte differentiation ➡ https://lnkd.in/dDZMmNfw #NoMoreCherryPicking #ScientificIntegrity #Biolaminin #cardiomyocyte #cellculture

    • Ingen alternativ bildtext i den här bilden
    • Ingen alternativ bildtext i den här bilden
  • Visa organisationssidan för BioLamina, grafik

    9 760 följare

    Thank you for meeting us at #ISSCR2024 in Hamburg last week. We were thrilled to celebrate with you our 15th anniversary, but also take you through our poster presentations, and welcome you to our innovation showcase. We loved to learn more about your research and discuss how our full-length Biolaminin® matrices can support your cell culture. Do you have a question about our Biolaminin® matrices? Contact us now ➡ https://lnkd.in/d8YvhRha See you next year in Hong Kong, International Society for Stem Cell Research!

    • Ingen alternativ bildtext i den här bilden
  • Visa organisationssidan för BioLamina, grafik

    9 760 följare

    It is really thrilling to hear about the most significant new advances in the stem cell research and regenerative medicine fields at #ISSCR2024! On this third day, don't miss the following poster presentations: 📌 From 3:45 to 4:45, Susanne Gröndahl from BioLamina will present poster #363 “Full-length laminins are crucial for recreating the cellular niche in vitro“ 📌 From 4:45 to 5:45, Dr. Malin Kele (Eriksson) will talk about how “Recombinant laminin proteins provide a biologically relevant niche for primary cells in vitro, mimicking the natural niche for both adult stem cells and cancer cells” in her poster #408 📌From 4:45 to 5:45, Dr. Diana Chaker from INSERM, will present her poster #338 : "Generation and characterization of clinical grade human master cell banks of induced pluripotent stem cells (iPSC) with high expansion potential." Come and see how our Biolaminin® 521 Clinical Therapy Grade (CTG) and Biolaminin 521 MX were used in her scalable protocol. Bis bald! Want to learn more about our full-length laminins? Come to our booth #903 until 6:00.

  • Visa organisationssidan för BioLamina, grafik

    9 760 följare

    Our Innovation Showcase at #ISSCR2024 starts in 30 minutes! Join us at Hall G2, Level 2, and hear from our guest speakers, Dr. Brian Hawkins and Dr. Terri Gaskell their journey toward translational success. Dr. Ilse Eidhof will also present how defined culture conditions robustly maintain human stem cell pluripotency via tightly controlled Ca2+ signaling. Refreshments will be served and you will get the opportunity to be one of our lucky winners of a gift card!

    • Ingen alternativ bildtext i den här bilden
    • Ingen alternativ bildtext i den här bilden
  • Visa organisationssidan för BioLamina, grafik

    9 760 följare

    Don't miss these poster sessions in a bit! ➡ From 3:45 to 4:45, Dr. Malin Kele (Eriksson), our Director Business Development, will present poster #269: “Gene editing cells using CRISPR-Cas9 on Biolaminin® 521 improves single-cell survival and cloning, enabling consecutive differentiation of human pluripotent stem cells on biorelevant matrices” ➡ Also from 3:45 to 4:45, you might be interested in Charlotte Janssens 's poster presentation #559 "Xeno/feeder-free culture using laminin supports resetting towards naive pluripotency in human embryonic stem cells". Check how her team at the Research Group Reproduction and Genetics, Vrije Universiteit Brussel, aimed to mimic the natural environment by culturing cells on Biolaminin® LN 521, which is one of the first cell adhesion proteins present in the inner cell mass of human blastocysts. ➡ From 4:45 to 5:45, don't miss Dr. Therese Kallur, our CSO and VP Business Development! She will present poster #254 “Organ-specific expression data steer choice of laminin proteins for in vitro studies, for biologically relevant drug discovery and development platforms” See you there, bis bald!

  • Visa organisationssidan för BioLamina, grafik

    9 760 följare

    See you tomorrow in Hamburg for #ISSCR2024! Come by our booth #903. We would love to learn more about your research and discuss how our full-length Biolaminin® matrices can support your cell culture. Here are some activities we have for you: 🌟 Thursday, July 11 from 3:45 to 4:45: Poster #269:“Gene editing cells using CRISPR-Cas9 on Biolaminin® 521 improves single-cell survival and cloning, enabling consecutive differentiation of human pluripotent stem cells on biorelevant matrices” 🌟 Thursday, July 11 from 4:45 to 5:45: Poster #254: “Organ-specific expression data steer choice of laminin proteins for in vitro studies, for biologically relevant drug discovery and development platforms” 🌟 Thursday, July 11 from 6:00 to 6:30 Don't miss our Innovation showcase: “Biolaminin® technology: supporting standardization for translational success”- Dr. Brian Hawkins, from Pluristyx, Inc., and Dr. Terri Gaskell, from Rinri Therapeutics Ltd., will share their stories of translational success. Dr. Ilse Eidhof, from Lund University/ Karolinska Institute, will share how defined culture conditions robustly maintain human stem cell pluripotency via tightly controlled Ca2+ signaling. Pre-register now for our innovation showcase ➡ https://lnkd.in/dsgtQEX9 🌟 Friday, July 12 from 3:45 to 4:45: Poster #363: “Full-length laminins are crucial for recreating the cellular niche in vitro“ 🌟Friday, July 12 from 4:45 to 5:45: Poster #408: “Recombinant laminin proteins provide a biologically relevant niche for primary cells in vitro, mimicking the natural niche for both adult stem cells and cancer cells” Bis bald!

    • Ingen alternativ bildtext i den här bilden
  • Visa organisationssidan för BioLamina, grafik

    9 760 följare

    Fascinating results just published in Developmental Cell demonstrate the foundational role of laminins in stem cell maintenance and differentiation in early embryos.  The results of this study align with the widely accepted view that full-length laminin: ➡ is the first and founding component of the crucial supportive layer that guides cell development: the basement membrane  ➡once produced, directly binds to cell surfaces and builds an independent network via self-assembly  ➡ regulates cell differentiation and tissue development already early in development.   Rosner and Hengstschläger examined how the basement membrane forms and breaks down during in vitro embryo development. They identify key structural components and receptors within the BM and demonstrate the importance of Oct4 in regulating BM development, including laminin assembly. Read the publication ➡ https://lnkd.in/dGb-zUdj 𝑃𝑖𝑐𝑡𝑢𝑟𝑒 𝑑𝑒𝑠𝑐𝑟𝑖𝑝𝑡𝑖𝑜𝑛: 𝑂𝑐𝑡4 𝑎𝑓𝑓𝑒𝑐𝑡𝑠 𝑙𝑎𝑚𝑖𝑛𝑖𝑛 𝑎𝑠𝑠𝑒𝑚𝑏𝑙𝑦 𝑑𝑢𝑟𝑖𝑛𝑔 𝑖𝑛 𝑣𝑖𝑡𝑟𝑜 𝑒𝑚𝑏𝑟𝑦𝑜𝑔𝑒𝑛𝑒𝑠𝑖𝑠. 𝐶𝑜𝑛𝑓𝑜𝑐𝑎𝑙 𝑖𝑚𝑎𝑔𝑒𝑠 𝑠ℎ𝑜𝑤𝑖𝑛𝑔 𝑜𝑟𝑡ℎ𝑜𝑔𝑜𝑛𝑎𝑙 𝑝𝑙𝑎𝑛𝑒𝑠 𝑜𝑓 𝑐𝑜𝑛𝑡𝑟𝑜𝑙- 𝑎𝑛𝑑 𝑂𝑐𝑡4-𝑑𝑒𝑝𝑙𝑒𝑡𝑒𝑑 𝑒𝑚𝑏𝑟𝑦𝑜𝑖𝑑𝑠 𝑖𝑛 𝑡ℎ𝑒 𝑒𝑥𝑝𝑒𝑟𝑖𝑚𝑒𝑛𝑡𝑎𝑙 𝑠𝑒𝑡𝑡𝑖𝑛𝑔𝑠 𝑑𝑒𝑠𝑐𝑟𝑖𝑏𝑒𝑑 𝑖𝑛 𝑡ℎ𝑒 𝑝𝑢𝑏𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛 𝑏𝑦 𝑅𝑜𝑠𝑛𝑒𝑟 𝑎𝑛𝑑 𝐻𝑒𝑛𝑔𝑠𝑡𝑠𝑐ℎ𝑙𝑎̈𝑔𝑒𝑟, 2024 𝐷𝑒𝑣𝑒𝑙𝑜𝑝𝑚𝑒𝑛𝑡 𝐶𝑒𝑙𝑙.

    Oct4 controls basement membrane development during human embryogenesis

    Oct4 controls basement membrane development during human embryogenesis

    sciencedirect.com

  • Visa organisationssidan för BioLamina, grafik

    9 760 följare

    Pluripotent stem cell (#PSC)-derived #cardiomyocytes play a key role in therapies of the future, serving directly as cellular therapy, as source material for tissue-specific extracellular vesicles, and as a platform for drug development. This requires standardized, reproducible, and efficient derivation of cardiomyocytes. This application note describes a published method on how to derive #xenofree and defined cardiovascular progenitor (CVP) cells and cardiomyocytes (CM) at high efficiency with a combination of Biolaminin® 521 and #Biolaminin 221 substrates (Lynn Yap et al. 2019 and 2023). The method is twice as efficient as other standardized substrates. The cells mature and display critical functional features, such as contraction and electrophysiological signatures, improving heart function over time after successful integration into infarcted pig hearts. Learn more about it ➡ https://lnkd.in/dVmrrZPs

    Cardiomyocyte differentiation on combination of full-length Biolaminin® 521 (LN521) and Biolaminin 221 (LN221) substrates

    biolamina.com

Liknande sidor